Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806390 · ClinicalTrials.gov registry record · Phase 4
Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00806390 is a Phase 4 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 15 participants.
The verdict
NCT00806390, a Phase 4 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate whether giving prophylactic metoprolol prior to and during anthracycline or trastuzumab therapy will decrease the incidence of anthracycline-induced cardiomyopathy. Patients are randomized to receive metoprolol or no treatment prior to anthracycline or trastuzumab treatment. The ejection fraction, as measured by nuclear ventriculography is measured before and after treatment.
Interventions
- DRUG Metoprolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806390
The ClinicalTrials.gov registry entry for NCT00806390 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metoprolol is the first listed.
NCT00806390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00806390 about?
NCT00806390 is a clinical study titled "Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol". The primary objective of this study is to investigate whether giving prophylactic metoprolol prior to and during anthracycline or trastuzumab therapy will decrease the incidence of anthracycline-induced cardiomyopathy. Patients are randomized to receive metoprolol or no treatment prior to anthracycl...
What is the current status of trial NCT00806390?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2008-07. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00806390?
The interventions under investigation include: Metoprolol (DRUG).
Who is sponsoring clinical trial NCT00806390?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.